1MEISSNER H C,TOWNSEND T,WENMAN W,et al.Hematologic effects of linezolid in young children[J].Pediatr Infect Dis J,2003,22(9 Suppl):186-192.
2PLACHOURAS D,GIANNITSIOTI E,ATHANASSIA S,et al.No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment[J].Clin Infect Dis,2006,43(9):89-91.
3KOHNO S,YAMAGUCHI K,AIKAWA N,et al.Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan[J].J Antimicrob Chemother,2007,60(6):1361-1369.
4NASRAWAY S A,SHORR A F,KUTER D J,et al.Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia:comparative analysis of linezolid and vancomycin use[J].Clin Inject Dis,2003,37(12):1609-1616.
5BIRMINGHAM M C,RAYNER C R,MEAGHER A K,et al.Linezolid for the treatment of multidrug-resistant,grampositive infections:experience from a compassionate-use program[J].Clin Infect Dis,2003,36(2):159-168.
6BERNSTEIN W B,TROTTA R F,RECTOR J T,et al.Mechanisms for linezolid-induced anemia and thrombocytopenia[J].Ann Pharmacother,2003,37(4):517-520.
7SORIANO A,ORTEGA M,GARCIA S,et al.Comparative study of the effects of pyridoxine,rifampin,and renal function on hematological adverse events induced by linezolid[J].Antimicrob Agents Chemother,2007,51(7):2559-2563.
同被引文献87
1Aneziokoro CO, Cannon JP, Pachucki CT, et al. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis [J]. J Chemother, 2005, 17 (6) : 643-650.
2Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program [J]. Clin Infect Dis, 2003, 36(2) : 159-68.
3Attassi K, Hershberger E, Alam R, et al. Thromboeytopenia associated with linezolid therapy[J]. Clin Infect Dis, 2002, 34(5 ) : 695 -698.
4Matsumoto K, Takeshita A, lkawa K, et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunctinn[J], Int J Antimierob Agents. 2010, 36(2) : 179-181.
6Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability [J]. Biopharm Drug Dispos, 2001, 22(3) : 91-97.
7Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia [J]. Stand J Infect Dis, 2012, 44(1) : 60-64.
8Cai Y, Chai D, Falagas ME, ctal. Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial[J]. J Antibiot (Tokyo), 2012,65(4) : 175- 178.
9Gorchynski J, Rose JK. Complications of MRSA treatment: linezolid-induced myelosuppression presenting with pancytopenia [ J ]. West J Emcrg Meal, 2008, 9(3) : 177-178.
